Willem Vanheeckeren, MD
Hematology & Oncology · Cleveland, OHNPI 1306931761
Payments from drug & device makers
Across 95 payments — averaging $30.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dova Pharmaceuticals$1K
- Eisai Inc.$137
- Takeda Pharmaceuticals U.S.A., Inc.$125
- Sanofi$101
- Amgen$97
- Tesaro, Inc.$86
- plus $954 from 32 others
What the payments were for
- Consulting fees$1,25044%
- Food & beverage$1,52053%
- Education$863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dova Pharmaceuticals | 3 | $1,356 |
| Eisai Inc. | 6 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $125 |
| Sanofi | 6 | $101 |
| Amgen | 6 | $97 |
| Tesaro, Inc. | 4 | $86 |
| Merck | 5 | $64 |
| Bristol Myers Squibb | 3 | $57 |
| GSK | 3 | $57 |
| AstraZeneca(2 entities) | 4 | $53 |
| Exelixis Inc. | 4 | $53 |
| Bayer | 3 | $50 |
| Astellas Pharma US Inc | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $46 |
| Genentech USA, Inc. | 3 | $46 |
| Lexicon Pharmaceuticals, Inc. | 1 | $40 |
| Johnson & Johnson(2 entities) | 3 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $32 |
| Lilly USA, LLC | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 2 | $31 |
| Shionogi Inc | 2 | $28 |
| Boehringer Ingelheim | 2 | $26 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $25 |
| Mylan Institutional Inc. | 2 | $24 |
| Daiichi Sankyo Inc. | 2 | $24 |
| Novartis | 2 | $24 |
| EMD Serono, Inc. | 2 | $23 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $15 |
| Seagen Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
| Puma Biotechnology, Inc. | 1 | $12 |
| Gilead | 1 | $12 |
| Portola Pharmaceuticals, LLC | 1 | $11 |
| Octapharma USA, Inc. | 1 | $11 |
| Clovis Oncology, Inc. | 1 | $11 |
| Pfizer | 1 | $11 |
| AbbVie | 1 | $11 |
| Rigel Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DOPTELET$1,250
How this compares
$2,856 in reported general payments places this provider in the 40th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 70 | $1,208,773 |
| Lenalidomide | 50 | $671,908 |
| OjjaaraMomelotinib Dihydrochloride | 21 | $576,538 |
| PomalystPomalidomide | 27 | $531,454 |
| VenclextaVenetoclax | 69 | $526,854 |
| BrukinsaZanubrutinib | 31 | $462,258 |
| TasignaNilotinib Hcl | 20 | $285,829 |
| EliquisApixaban | 132 | $126,879 |
| ImbruvicaIbrutinib | 12 | $62,468 |
| XareltoRivaroxaban | 31 | $23,502 |
| PromactaEltrombopag Olamine | 11 | $21,956 |
| Imatinib Mesylate | 14 | $20,575 |
| OxycontinOxycodone Hcl | 13 | $7,470 |
| Enoxaparin Sodium | 19 | $5,565 |
| Dapsone | 47 | $3,543 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $57 | $1,208,77370 claims |
| GSKOjjaara | $57 | $576,53821 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $46 | $531,45427 claims |
| AbbVieVenclexta | $11 | $526,85469 claims |
| NovartisTasigna, Promacta | $24 | $307,78531 claims |
| PfizerEliquis | $11 | $126,879132 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $25 | $62,46812 claims |
| Johnson & JohnsonXarelto | $39 | $23,50231 claims |
| Lilly USA, LLCOlanzapine | $32 | $34712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cleveland
- Afshin DowlatiCleveland$25.1M
- Brian HillCleveland$11.6M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
- Nathan PennellCleveland$3.8M
- Ankit ManglaCleveland$3.3M
- David BajorCleveland$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.